Last updated: February 15, 2026
Overview of Product and Market Context
NDC 60505-4318 corresponds to Polatuzumab vedotin-piiq (Polivy), a monoclonal antibody–drug conjugate approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It was approved by the FDA in June 2019 for combination therapy with bendamustine and rituximab. The drug’s approval expanded options for relapsed DLBCL patients, addressing unmet needs in relapsed/refractory cases.
The Latvian market and wider U.S. market for polatuzumab are characterized by high unmet clinical needs, limited alternatives, and strong reimbursement pathways due to its orphan status.
Market Size and Growth Dynamics
Global Market Size:
- Estimated to reach approximately $800-900 million in revenue by 2025.
- U.S. sales account for approximately 70% of this value, driven by labeling scope, reimbursement FDA approval, and the prevalence of relapsed DLBCL.
Market Drivers:
- Increasing incidence of non-Hodgkin lymphoma (NHL), notably DLBCL, which accounts for roughly 30-40% of all NHL cases.
- A growing number of relapsed/refractory cases due to recent treatment failures with first-line therapies.
- Expansion of indications within hematologic malignancies, including potential off-label uses.
Competitive Landscape:
- Main competitors include CAR-T therapies (e.g., axicabtagene ciloleucel, tisagenlecleucel), which are frequently used in relapsed settings.
- Polatuzumab's advantage lies in its manageable side-effect profile and relatively lower cost compared to CAR-T therapy.
Current Pricing and Reimbursement Landscape
List Price:
- The wholesale acquisition cost (WAC) for Polatuzumab vedotin is approximately $13,000 to $15,000 per vial.
- The typical treatment regimen involves multiple doses, with an average course costing $120,000 to $180,000 per patient, depending on dosing and number of cycles.
| Pricing Benchmarks: |
Parameter |
Data |
| Price per vial |
$13,500 (average) |
| Typical course |
6 doses over 3 cycles (~$80,000–$100,000) |
| Cost per patient |
$120,000–$180,000 |
Reimbursement Dynamics:
- Reimbursement is primarily through CMS and private insurers, with coding under Medicare using ICD-10 codes specific for relapsed/refractory DLBCL.
- The drug typically falls under oncology bundled payment models; thus, pricing negotiations are critical for maximizing profitability.
Price Projections and Market Penetration
Short-term Outlook (Next 1-2 Years):
- Stable pricing due to high demand and limited direct competition.
- Price support from FDA approval, expanded labeling, and managed care coverage.
- Anticipate prices staying within the current range, with potential minor increases aligned with inflation or manufacturing cost adjustments.
Medium-term Outlook (Next 3-5 Years):
- With potential label expansion to earlier lines of therapy or additional indications (e.g., follicular lymphoma), demand may increase.
- Entry of biosimilar or alternative therapies could exert downward pressure; however, complex conjugate structures pose manufacturing challenges, limiting immediate biosimilar availability.
- Overall price stability is expected unless new competitors or reforms influence market dynamics.
Long-term Outlook (Beyond 5 Years):
- Possible price erosion due to biosimilar development or commoditization of antibody-drug conjugates.
- Market share could shift toward combination therapies or novel biologics.
Regulatory and Economic Factors Affecting Price
- Orphan drug designation: Extends exclusivity periods (7 years in the US), supporting sustained pricing.
- Price negotiations: CMS and private payers increasingly scrutinize high-cost oncology drugs.
- Manufacturing costs: Conjugate antibody production costs limit price reductions initially but could decrease with technological advances.
Risks and Opportunities
| Risks |
Opportunities |
| Entry of biosimilars or generics |
Increasing indication scope, expanding market size |
| Regulatory delays or restrictions |
Price increases driven by additional approved indications |
| Reimbursement changes |
Cost reduction initiatives in healthcare settings |
Key Takeaways
- NDC 60505-4318 (Polatuzumab vedotin) revenues are projected to hover around $120-180K per course, with minimal short-term price reductions.
- Market growth hinges on expanding indications, competitive landscape developments, and reimbursement policies.
- Long-term shifts depend on biosimilar entry and technological advancements lowering manufacturing costs.
Frequently Asked Questions
1. How does Polatuzumab vedotin compare in price to similar therapies?
Its per-course cost (~$120,000–$180,000) exceeds traditional chemotherapies but is less expensive than CAR-T therapies, which can exceed $400,000 per treatment.
2. What factors could impact future pricing?
Biosimilar development, indication expansion, reimbursement policy changes, and manufacturing cost reductions.
3. How long can the current price remain stable?
With orphan status and limited immediate biosimilar competition, prices are expected to remain stable over the next 3 years.
4. Are there regional pricing variations?
Yes. U.S. prices are typically higher than European or Asian markets due to reimbursement policies, healthcare costs, and market size differences.
5. What is the potential impact of new indications?
Additional approvals could increase demand and allow for price negotiations that favor higher pricing strategies.
References
[1] FDA. Polatuzumab vedotin (Polivy) approval summary. 2019.
[2] IQVIA. Oncology market insights, 2022-2025 projection data.
[3] CMS billing and reimbursement codes. Centers for Medicare & Medicaid Services.
[4] EvaluatePharma. Oncology drug market outlook, 2023.
[5] Manufacturer pricing and cost data. Confidentially sourced.
